NCT05067634
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Registry fields
- Overall status
- COMPLETED
- Conditions
- Partial Epilepsy
- Study type
- INTERVENTIONAL
- Phase
- PHASE3
- Primary purpose
- TREATMENT
- Intervention type
- DRUG
- Interventions
- Xcopri
- Lead sponsor
- SK Life Science, Inc. (INDUSTRY)
Cached at: 2026-10-23 21:36:54
Brief summary
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue